Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22734544 | 0.88 | KMT2A (0.41) | KMT2AMEN1ALDH1A1F10SMN1; SMN2 | |
| SCHEMBL29440722 | 0.88 | KMT2A (0.41) | KMT2AMEN1ALDH1A1F10SMN1; SMN2 | |
| SCHEMBL22734566 | 0.87 | KMT2A (0.38) | KMT2AMEN1ALDH1A1F10SMN1; SMN2 | |
| SCHEMBL29440696 | 0.87 | KMT2A (0.38) | KMT2AMEN1ALDH1A1F10SMN1; SMN2 | |
| SCHEMBL22764081 | 0.85 | ALDH1A1 (0.35) | KMT2AMEN1ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL22734534 | 0.84 | KMT2A (0.42) | KMT2AMEN1ALDH1A1F10SMN1; SMN2 | |
| SCHEMBL22734600 | 0.83 | KMT2A (0.41) | KMT2AMEN1ALDH1A1F10SMN1; SMN2 | |
| SCHEMBL29440697 | 0.83 | KMT2A (0.41) | KMT2AMEN1ALDH1A1F10SMN1; SMN2 | |
| SCHEMBL22734543 | 0.83 | KMT2A (0.41) | KMT2AMEN1ALDH1A1F10SMN1; SMN2 | |
| SCHEMBL21875779 | 0.82 | CNR1 (0.37) | KMT2AMEN1ALDH1A1MAPK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | ELANCO TIERGESUNDHEIT AG (CH) | 2025-10-21 | — | — | US | claimed |
| CN-114206860-B | Bicyclic derivatives for the treatment of endoparasites | 礼蓝动物保健有限公司 | 2025-02-18 | — | — | CN | claimed |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (SZ) | 2024-10-31 | — | — | US | claimed |
| CN-116888124-A | Bicyclic derivatives | 礼蓝动物保健有限公司 | 2023-10-13 | — | — | CN | claimed |
| EP-4255911-A1 | BICYCLIC DERIVATIVES | Elanco Tiergesundheit AG (CH) | 2023-10-11 | — | — | EP | claimed |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-08-04 | — | — | US | claimed |
| WO-2022117783-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2022-06-09 | — | — | WO | claimed |
| EP-3980414-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | Elanco Tiergesundheit AG (CH) | 2022-04-13 | — | — | EP | claimed |
| CN-114206860-A | Bicyclic derivatives for the treatment of endoparasites | 礼蓝动物保健有限公司 | 2022-03-18 | — | — | CN | claimed |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG | 2020-12-10 | — | — | US | claimed |
| WO-2020247747-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2020-12-10 | — | — | WO | claimed |
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | ELANCO TIERGESUNDHEIT AG (CH) | 2025-10-21 | — | — | US | disclosed |
| CN-114206860-B | Bicyclic derivatives for the treatment of endoparasites | 礼蓝动物保健有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (SZ) | 2024-10-31 | — | — | US | disclosed |
| WO-2024213752-A1 | LONG-TERM PREVENTION AND/OR TREATMENT OF A DISEASE BY SLO-1 INHIBITORS | ELANCO ANIMAL HEALTH GMBH (DE) | 2024-10-17 | — | — | WO | disclosed |
| CN-114206860-A | Bicyclic derivatives for the treatment of endoparasites | 礼蓝动物保健有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG | 2020-12-10 | — | — | US | disclosed |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG | 2020-12-10 | — | — | US | disclosed |
| WO-2020247747-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2020-12-10 | — | — | WO | disclosed |
| WO-2020247747-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12448391-B2 | Bicyclic derivatives for treating endoparasites | TBXA2R, PIGS, CYCS | KMT2A 2765/4885MEN1 2037/4885ALDH1A1 1017/4885 |
| US-20240360116-A1 | BICYCLIC DERIVATIVES | FABP3, CYCS, TNNI3 | KMT2A 2925/4885MEN1 2797/4885ALDH1A1 611/4885 |
| US-20220242857-A1 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | TBXA2R, PIGS, CYCS | KMT2A 2765/4885MEN1 2037/4885ALDH1A1 1017/4885 |
| US-20200385398-A1 | NEW BICYCLIC DERIVATIVES | CYCS, FABP3, TNNI3 | KMT2A 3657/4885MEN1 3381/4885ALDH1A1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.